HOME > News Releases > Start of Marketing of Anti-inflammatory Analgesic Patch Formulations Containing Flurbiprofen

Start of Marketing of Anti-inflammatory Analgesic Patch Formulations Containing Flurbiprofen

January 31, 2013

Taisho Pharmaceutical Holdings Co., Ltd. has announced that consolidated subsidiary Taisho Toyama Pharmaceutical Co., Ltd. (“Taisho Toyama Pharmaceutical”) [Head Office: Toshima-ku, Tokyo; President: Akira Ohira] will begin marketing prescription pharmaceutical anti-inflammatory analgesic patch formulations YAKUBAN® Tape, STAYBAN® Pap and FULRUBAN® PAP from April 1, 2013. These products contain Flurbiprofen as an active ingredient.

At present, YAKUBAN® Tape is manufactured by TOKUHON Corporation (“TOKUHON”) [Head Office: Minato-ku, Tokyo; President: Yoshio Tanabe] and marketed by Mitsubishi Tanabe Pharma Corporation (“Mitsubishi Tanabe Pharma”) [Head Office: Chuo-ku, Osaka; President: Michihiro Tsuchiya] and Kaken Pharmaceutical Co., Ltd. (“Kaken Pharmaceutical”) [Head Office: Bunkyo-ku, Tokyo; President: Tetsuo Onuma]. Meanwhile, STAYBAN® Pap is manufactured by TOKUHON and marketed by Mitsubishi Tanabe Pharma and Yutoku Pharmaceutical Ind. Co., Ltd. (“Yutoku Pharmaceutical”) [Head Office: Kashima City, Saga; President: Keiichi Ueno]. FULRUBAN® PAP is manufactured by Taikyo Pharmaceutical Co., Ltd. [Head Office: Toyama City, Toyama; President: Junichi Ishikuro] and marketed by Mitsubishi Tanabe Pharma (through TOKUHON), Kaken Pharmaceutical and Mikasa Seiyaku Co., Ltd. [Head Office: Nerima-ku, Tokyo; President: Takumi Ogata].

Taisho Toyama Pharmaceutical will begin marketing activities presently conducted by Mitsubishi Tanabe Pharma and Yutoku Pharmaceutical from April 1, 2013, following the termination of marketing consignment contracts with TOKUHON and Mitsubishi Tanabe Pharma and Yutoku Pharmaceutical.

Taisho Toyama Pharmaceutical is a core prescription pharmaceuticals marketing company of the Taisho Pharmaceutical Group in Japan. The company focuses on its two priority fields of infectious diseases and inflammatory/immunologic diseases. With today’s announcement, Taisho Toyama Pharmaceutical will expand its lineup in the inflammatory/immunologic diseases field. For its part, TOKUHON, as a member of the Taisho Pharmaceutical Group, should be able to maximize sales of the aforementioned products through cooperation with Taisho Toyama Pharmaceutical and also be able to respond to diverse needs at the medical frontlines, thereby contributing to improved patient quality of life.



New Releases

News Releases from Our Group Companies